e-learning
resources
Virtual 2021
07.09.2021
New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rheumatoid arthritis-associated interstitial lung disease: time trends
B. Samhouri (Rochester, United States of America), C. Crowson (Rochester, United States of America), S. Achenbach (Rochester, United States of America), V. Kronzer (Rochester, United States of America), J. Davis (Rochester, United States of America), E. Myasoedova (Rochester, United States of America), R. Vassallo (Rochester, United States of America)
Source:
Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Session:
New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Session type:
Oral Presentation
Number:
2969
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Samhouri (Rochester, United States of America), C. Crowson (Rochester, United States of America), S. Achenbach (Rochester, United States of America), V. Kronzer (Rochester, United States of America), J. Davis (Rochester, United States of America), E. Myasoedova (Rochester, United States of America), R. Vassallo (Rochester, United States of America). Rheumatoid arthritis-associated interstitial lung disease: time trends. 2969
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Rheumatoid arthritis-associated lung disease
Source: Eur Respir Rev 2015; 24: 1-16
Year: 2015
The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management
Year: 2018
Rheumatoid arthritis-related lung disease
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2016; 47: 588-596
Year: 2016
Interstitial lung disease in patients with rheumatoid arthritis
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008
Mortality and clinical features in rheumatoid arthritis and interstitial lung disease
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017
Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2010; 35: 1206-1208
Year: 2010
Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new
Source: Breathe, 16 (4) 200223; 10.1183/20734735.0223-2020
Year: 2020
Methotrexate and rheumatoid arthritis associated interstitial lung disease
Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020
Year: 2021
Duration of rheumatoid arthritis and the risk of developing interstitial lung disease
Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020
Year: 2021
Characteristics and predictors of outcome in rheumatoid arthritis related ILD
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018
Year: 2019
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J 2010; 35: 1322-1328
Year: 2010
Destructive bronchiolitis: a characteristic pathological feature of interstitial lung disease preceding the onset of rheumatoid arthritis
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Risk factors of interstitial lung diseases in patients with rheumatoid arthritis.
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019
Rheumatoid arthritis and comorbid chronic obstructive or interstitial pulmonary diseases: Prevalence in a population-based cohort
Source: International Congress 2016 – Burden of respiratory diseases: from environmental aspects to healthcare consumption
Year: 2016
Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy
Source: International Congress 2014 – ILDs 4
Year: 2014
Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease
Source: Eur Respir J, 57 (5) 2002533; 10.1183/13993003.02533-2020
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept